Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 4 Interventional Results available

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women

NCT02783170
View directory record Official record
Conditions
Pregnancy
Interventions
Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 31, 2026, 6:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT04772170
View directory record Official record
Conditions
Influenza, Respiratory Virus, Coronavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants

NCT00000873
View directory record Official record
Conditions
HIV Infections
Interventions
Infant Formula
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional Results available

HIV Screening in the Emergency Department Setting

NCT00667186
View directory record Official record
Conditions
HIV Infections
Interventions
Targeted Screening, Routine Screening
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
9,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

NCT02431273
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Prophylaxis
Interventions
TDF IVR, TDF-FTC IVR, TDF-FTC-MVC IVR
Drug
Lead sponsor
Auritec Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 31, 2026, 6:48 PM EDT
Enrolling by invitation No phase listed Observational

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

NCT06488846
View directory record Official record
Conditions
HIV Infections
Interventions
INVITE-Home, Clinic-Administered LAI-ART, Oral ART
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 6:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bone Marrow and Peripheral Blood Immune Responses Study

NCT05616546
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

NCT00957996
View directory record Official record
Conditions
Seasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
79
States / cities
Dothan, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional

A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine

NCT00002280
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 31, 2026, 6:48 PM EDT
Completed No phase listed Observational

Tissue Drug Levels of HIV Medications

NCT01490346
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Initiation of anti-retroviral therapy
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 6:48 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00010127
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001062
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional Results available

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

NCT00125762
View directory record Official record
Conditions
Cirrhosis, Hepatitis B, Hepatitis C
Interventions
FibroScan
Device
Lead sponsor
Afdhal, Nezam, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NOWDx Test for the Detection of Antibodies to COVID-19

NCT04690413
View directory record Official record
Conditions
COVID-19, SARS-CoV-2, Coronavirus
Interventions
NOWDx COVID-19 Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Tucson, Arizona • West Palm Beach, Florida • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

NCT02873260
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV005, rDEN3Δ30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 31, 2026, 6:48 PM EDT
Recruiting Not applicable Interventional

Care for Veterans Post-COVID-19

NCT05787379
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Concordant Care Training, Education Packet Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 6:48 PM EDT
Completed No phase listed Observational

Evaluation and Natural History of Children With Cancer and AIDS

NCT00001424
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Cancer, HIV Infections, Leukemia, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients

NCT00017823
View directory record Official record
Conditions
HIV Infections
Interventions
Acupressure
Procedure
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2010 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

NCT02715479
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, BMS955176
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

NCT02480712
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 31, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study

NCT05977881
View directory record Official record
Conditions
HIV Infections
Interventions
CHECKIT!
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 6:48 PM EDT